KYTX News

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025